Treatment for relapsed Hodgkin lymphoma: refinement of chemotherapy or targeted treatment?

Related Articles

Treatment for relapsed Hodgkin lymphoma: refinement of chemotherapy or targeted treatment?

Expert Opin Pharmacother. 2011 Apr;12(6):991-4

Authors: Doggrell SA

Abstract
The prognosis for those with relapsed Hodgkin lymphoma is poor. This evaluation is of two new approaches to the treatment of relapsed Hodgkin lymphoma. First, is a refinement of the chemotherapy for the relapsed condition, which showed that adding SHDCT (sequential high-dose chemotherapy of cyclophosphamine, uromitexane, granulocyte colony-stimulating factor, methotrexate, vincristine, etoposide) did not improve outcome. Second, is new targeted treatment for relapsed Hodgkin disease--brentuximab vedotin, which has an antitubulin agent (monomethylauristatin E) attached to a CD30-specific antibody. This agent gave promising results in a Phase I clinical trial in subjects with relapsed Hodgkin lymphoma. Brentuximab vedotin has produced good initial findings in the treatment of Hodgkin lymphoma and needs to be tested more widely.

PMID: 21405939 [PubMed - in process]

http://ift.tt/2EFrAv0